TGTX Q1 2021 Earnings — TG Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TGTXTG Therapeutics, Inc.

$5B

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$793,000+1986.8% YoY

Gross Profit

$654,00082.5% margin

Operating Income

-$89M-11248.7% margin

Net Income

-$91M-11428.5% margin

EPS (Diluted)

$-0.69

QoQ Revenue Growth

+1986.8%

Cash Flow

Operating Cash Flow

-$81M

Free Cash Flow

-$81M

Stock-Based Comp.

$17M

Balance Sheet

Total Assets

$549M

Total Liabilities

$103M

Stockholders' Equity

$445M

Cash & Equivalents

$472M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$793,000	$38,000	+1986.8%
Gross Profit	$654,000	$38,000	+1621.1%
Operating Income	-$89M	-$50M	-77.5%
Net Income	-$91M	-$51M	-77.3%

Revenue Segments

Product

$755,00095%

License

$38,0005%